Sunitinib in Treating Patients With Advanced Malignant Pleural Mesothelioma

NCT00392444 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

39

Enrollment

NIH

Sponsor class

Conditions

Advanced Malignant Mesothelioma
Recurrent Malignant Mesothelioma

Interventions

DRUG: sunitinib malate

Sponsor

National Cancer Institute (NCI)